World’s First Approved Biosimilar toActemra ® Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stagebiopharmaceutical company, announced thattheChina National Medical Products Administration(NMPA) hasapproved BAT1806, a biosimilar of Actemra ® (tocilizumab)...
DetailsGuangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company,announced today that enrollment for the Phase I clinical study of BAT2022 hasbeen completed, showing that BAT2022 is well-tolerated and there were no DLTobserved up to the dose of ...
Guangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177) , a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8009, an antibody drug conjugate (ADC) that targets B7-H3 (CD276). The clinical trial is a multicent...
Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177) , a commercial-stage pharmaceuticalcompany, today announced that dosing has begun in a Phase 1 clinical study evaluatingBAT8006, an antibody drug conjugate (ADC) that targets folic acid receptor α(FRα). The clinical trial is...
